|
《Handbook of Modern Pharmaceutical Analysis 》， Edited by S Ahuja and S Scypinski, Academic Press, San Diego, 2001.
|
|
|
《药物分析》盛龙生，何丽一，徐连连，沈文斌编著化学工业出版社2002。 |
|
《Hepatology Digest》： Please simply introduce the non-invasive diagnosis of liver fibrosis and how about the status of clinical usage in France or Europe?
|
|
|
《国际肝病》：你能简单介绍一下无创性肝纤维化诊断技术以及其目前在法国临床应用的情况吗？ |
|
《Hepatology Digest》：Currently, more and more antiviral medicine launched to clinic, how to choose the idea antiviral medicine for treating chronic hepatitis B?
|
|
|
《国际肝病》：目前越来越多的治疗慢性乙型肝炎的抗病毒药物应用于临床，你认为如何选择这些抗病毒药物进行治疗？ |
|
《Hepatology Digest》：How do you prevent the progression of liver fibrosis and cirrhosis?
|
|
|
《国际肝病》：如何防止肝纤维化和肝硬化？ |
|
《Hepatology Digest》：What is the end point of the treatment of HBV?
|
|
|
慢乙肝抗病毒治疗的终点是什么？ |
|
《International Circulation》: Another question is: It was mentioned for the first time that ?-blockers are no longer preferred as a routine initial therapy for hypertension in British Hypertensive Society Guidelines 2006.
|
|
|
《国际循环》：还有一个问题：2006年英国高血压指南中，第一次提出了β受体阻滞剂不再是多数高血压患者的首选降压治疗药物。 |
|
《International Circulation》: Compare with the BP-lowering evaluation with brachial blood pressure or with the arterial hardness value.
|
|
|
《国际循环》：比较用肱动脉血压和动脉硬度值来衡量降压效果。 |
|
《International Circulation》: My last question is: today we issued the new guideline of hypertension, what are the major differences between this version of Guideline 2007 and the previous one?
|
|
|
最后一个问题：从新公布的高血压指南看来，这个版本的指南和上一个版本的指南之间有什么重要区别吗？ |
|
《International Circulation》:In recent years, the limitation of brachial blood pressure for BP-lowing evaluation has been known, while the obvious relationship between pressure gradient and cardiovascular events is found according to recent studies, some s
|
|
|
近年来，上臂血压作为降压指标的局限性已被大家所公认，而许多研究显示脉压与心血管事件存在显著相关性，为此许多学者建议应将动脉血管硬度作为评价高血压和选择药物选择的重要指标。 |
|
《International Circulation》：And my second question is for most patient with hypertension, they should take the anti-hypertensive drugs all their lives, now the pharmaco-eonomics has been an important part of hypertension research, what should we consider
|
|
|
我的第二个问题是对于大多数高血压患者而言，他们都需要终身服用抗高血压药物，而且目前药物经济学已经成为高血压研究与治疗中非常重要的组成部分，我们是否应该认真评价一下抗高血压药物的经济合理性，另外如何知道我们的临床指南呢？ |
|
《International Circulation》：Does pre-hypertension need additional drug treatment or only life style changes, according to your representation? And how do we prevent hypertension from pre-hypertension?
|
|
|
高血压前期的治疗需要药物治疗吗？或者只需要生活方式干预？我们如何预防高血压前期发展为高血压？ |
